<DOC>
	<DOC>NCT00686010</DOC>
	<brief_summary>To demonstrate the effect of JTT-705 doses from 300 mg to 900 mg on the elevation of HDL-C and on the inhibition of CETP activity versus placebo, in patients presenting with mild dyslipidaemia. These objectives will be tested after 4 weeks of treatment.</brief_summary>
	<brief_title>Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Dalcetrapib</mesh_term>
	<criteria>Patients with of Type II hyperlipidaemia Patients having lipid values as indicated below: HDLC &lt; 1.6 mmol/l TG &lt; 4.5 mmol/l Male and females between 18 and 65 years old (If female must be postmenopausal, or premenopausal and surgically sterile or using an acceptable form of contraception) Body Mass Index (BMI) &gt; 35 kg/mÂ² Pregnant, breast feeding, or woman with child bearing potential without an effective method of contraception Concomitant use of medications identified in the protocol</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>CETP Inhibitor</keyword>
	<keyword>HDL-C</keyword>
	<keyword>LDL-C</keyword>
	<keyword>Apolipoprotein</keyword>
</DOC>